[ad_1]
British pharmaceutical giant AstraZeneca on Sunday announced the “groundbreaking” results of a trial of a new breast cancer drug that it says has been shown to reduce the risk of death or disease progression by 72% , compared to existing treatments.
The pharmaceutical company said the results of its trial of the drug Enhertu in the treatment of currently incurable HER-2-positive breast cancer showed “a strong tendency to improve overall survival.”
AstraZeneca said that Enherthu, when combined with chemotherapy, has been shown to be twice as effective in controlling the disease as the similar intravenous antibody drug TDM1, the current benchmark drug.
Three-quarters of the 500 patients in the trial worldwide who received Enherthu showed no progression of their cancer after 12 months, compared with 34.1% of those treated with TDM1. In addition, progression-free survival improved from 7.2 months to 25.1 months.
A total of 94.1% of Enhertu patients survived 12 months of treatment, compared to 85.9% of MDD patients1.
Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, called the results “groundbreaking”.
“These unprecedented data represent a potential paradigm shift in the treatment of HER-2-positive metastatic breast cancer and illustrate the potential of Enhertu to transform the lives of more patients in earlier treatment settings,” a-t she said, announcing the results at the 2021 European Society of Medical Oncology Conference.
Vials of anti-breast cancer antibodies Enhertu produced by the drug manufacturer AstraZeneca. (AstraZeneca)
Enhertu was approved by the Food and Drug Administration in 2019 for inoperable or HER-2-positive metastatic breast cancer if the patient did not respond to standard treatment and at least two other combination options.
“With the remarkable results of this study, Enhertu could become the new gold standard treatment for patients with HER-2 positive metastatic breast cancer after standard chemotherapy”, Dr Sunil Verma, vice president and global clinical manager of breast cancer research at AstraZeneca, told ABC News following the company’s announcement.
According to the U.S. nonprofit Breastcancer.org, about one in eight women will develop invasive breast cancer in her lifetime, although the overall death rate has declined over the years, mainly due to advances in breast cancer. treatments and earlier detection through screening.
By 2021, some 250,000 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, and about 40,000 women in the United States are expected to die from the disease.
In addition, some 360,000 new cases of breast cancer are diagnosed and 92,000 deaths each year in Europe. In Israel, around 4,500 women are diagnosed each year and 900 die from it.
[ad_2]
Source link